Heron Therapeutics is trading 5.69% higher at $0.32, with no clear September 30 catalyst identified. - The price is up from the September 29 close of $0.31; no trading volume was provided. - A September 29 multi-product development and license agreement gives Heron exclusive U.S. rights to market certain products, but coverage does not link it to the gain. - Broader markets are higher, but no supplied index rose more than 0.5%.